Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.4, replacing v3.5.3, indicating a small version update to the ClinicalTrials.gov page rendering.
    Difference
    0.1%
    Check dated 2026-05-15T04:57:26.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page revision was bumped from v3.5.2 to v3.5.3, updating the page's metadata.
    Difference
    0.1%
    Check dated 2026-04-30T18:54:00.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2 on the page.
    Difference
    0.1%
    Check dated 2026-04-16T11:12:12.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-18T15:49:55.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 in the page footer.
    Difference
    0.1%
    Check dated 2026-03-11T14:22:29.000Z thumbnail image
  9. Check
    109 days ago
    Change Detected
    Summary
    Updated the page to Revision 3.4.2. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.
    Difference
    0.4%
    Check dated 2026-02-11T09:48:20.000Z thumbnail image

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.